Prophylactic or therapeutic agent for diabetic maculopathy

Details Prophylactic or therapeutic agent for diabetic maculopathy Prophylactic or therapeutic agent for diabetic maculopathy

2011-03-22

2011-03-22

Hartley, Michael G (Department: 1618)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

07910615

ABSTRACT:
A prophylactic or therapeutic agent for diabetic maculopathy, which can be administered for a long time and exhibits efficacy in a mechanism different from that of existing medicines. The invention relates to a prophylactic or therapeutic agent for diabetic maculopathy, comprising, as an active ingredient, a compound represented by the general formula:wherein X represents a halogen or a hydrogen atom, R1and R2concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1and R2, together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle. Preferably, the compound is (2S,4S)-6-fluoro-2′,5′-dioxospiro[chroman-4,4′-imidazolidine]-2-carboxamide. The invention also provides a model animal with diabetic maculopathy produced by subjecting a diabetic animal to intraocular ischemia/reperfusion to express edema in a retinal visual cell layer or in a macula lutea.

REFERENCES:
patent: 4740517 (1988-04-01), Kurono et al.
patent: 5639482 (1997-06-01), Crary
patent: 6426341 (2002-07-01), Mylari
patent: 6479729 (2002-11-01), Campochiaro et al.
patent: 0 719 556 (1996-07-01), None
patent: 1 106 210 (2001-06-01), None
patent: 61-200991 (1986-09-01), None
patent: 07-242547 (1995-09-01), None
patent: 08-231549 (1996-09-01), None
Lopes de Faria et al., Acta Ophthalmol Scand, 77, p. 170-175, 1999.
Definition of “prevent” from dictionary.com, accessed Nov. 28, 2007.
Definition of Maculopathy from Medicinenet.com, accessed Sep. 2, 2008.
Wani et al., JK Practitioner 10(4):275-278, 2003.
Speicher, Matthew A. et al., “Pharmacologic Therapy for Diabetic Retinopathy,” Expert Opinion on Emerging Drugs, vol. 8, No. 1 (2003), pp. 239-250.
Masahiko Akita et al., “Effects of and Aldose Reductase Inhibitor, SNK-860, on the Histopathological Changes of Retinal Tissues in a Streptozotocin-Induced Rat Model,” Acta Med. Okayama, vol. 47, No. 5 (1993), pp. 299-304.
Irina G. Obrosova et al., “Aldose Reductase Inhibitor Fidarestat Prevents Retinal Oxidative Stress and Vascular Endothelial Growth Factor Overexpression in Streptozotocin-Diabetic Rats,” Diabetes, vol. 52, No. 3 (2003), pp. 864 to 871.
Giebel, S.J. et al., “Upregulation of Extracelluar Proteinases and Angiopoietin 2 during Blood-Retinal-Barrier Alteration in the Diabetic Rat Model,” ARVO Annual Meeting Abstract Search and Program Planner, vol. 2003, pp. Abstract No. 3903.
Sima, J. et al., “Angiostatin Decrease Vascular Leakage by Down-Regulating VEGF Expression,” ARVO Annual Meeting Abstract Search and Program Planner, vol. 2003, pp. Abstract No. 363.
Nick Giannoukakis, Fidarestat, Sanwa Kagaku/NCCurex/Sankyo, Current Opinion in Investigational Drugs, 2003, vol. 4, No. 10, pp. 1233-1239.
Frederick L. Ferris, III, MD, “Evaluation of New Treatment Paradigms for Diabetic Retinopathy and Macular Edema,” Survey of Ophthalmology, vol. 47, Supplement 2, Dec. 2002, p. S237.
MacGregor, Leslie C., et al. “Experimental Diabetes Mellitus Impairs the Function of the Retinal Pigmented Epithelium”,Metabolism, vol. 35, No. 4, Suppl. 1 (Apr. 1986), p. 28-34.
Ferris III, Frederick L., “Foreword: Evaluation of New Treatment Paradigms for Diabetic Retinopathy and Macular Edema”,Survey of Ophthalmology, vol. 47, Suppl. 2 (Dec. 2002), p. S237.

Affiliated with

Also associated with

Rating

Prophylactic or therapeutic agent for diabetic maculopathy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prophylactic or therapeutic agent for diabetic maculopathy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prophylactic or therapeutic agent for diabetic maculopathy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2700562